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Abstract
Background—Since 1960, the Advisory Committee on Immunization Practices (ACIP) has 
recommended influenza vaccination for adults with certain high-risk conditions because of 
increased risk for complications from influenza infection. We assessed national influenza 
vaccination among persons 18-64 years with high-risk conditions.
Methods—We analyzed data from the 2012 and 2013 National Health Interview Survey (NHIS). 
The Kaplan-Meier survival analysis procedure was used to estimate the cumulative proportion of 
influenza vaccination among adults 18-64 years with high-risk conditions. Potential missed 
opportunities for influenza vaccination were also evaluated. Multivariable logistic regression and 
predictive marginal analyses were conducted to identify factors independently associated with 
vaccination.
Results—Overall, 39.9 million adults 18-64 years (18.9%) had at least one high-risk condition. 
For adults 18-64 years with high-risk conditions, overall influenza vaccination coverage was 
49.5%. Coverage among adults 50-64 years was significantly higher compared with those 18-49 
years (59.3% vs. 39.0%; p<0.05). Among adults 18-64 years, coverage was 46.2% for those with 
chronic lung diseases, 50.5% for those with heart disease, 58.0% for those with diabetes, 62.5% 
for those with renal disease, and 56.4% for those with cancer. Overall, 90.1% reported at least one 
visit to a health care setting where vaccination could have been provided. Among adults 18-64 
years with high-risk conditions, older age, being female, Hispanic ethnicity or Asian race, having 
one or more physician visits, a regular physician for health care, health insurance, and having ever 
received pneumococcal vaccination were independently associated with a higher likelihood of 
influenza vaccination. Being widowed/divorced/separated or never married and not being 
employed were independently associated with a lower likelihood of influenza vaccination
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Conclusions—Influenza vaccination coverage varies substantially by age and high-risk 
conditions but remains low. Approximately 50% of those with high-risk conditions remain 
unvaccinated. Healthcare providers should ensure they routinely assess influenza vaccination 
status, recommend and offer vaccines to those with high-risk conditions.
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Introduction
Persons with underlying health-risk conditions such as asthma, bronchitis, emphysema, 
chronic obstructive pulmonary disease (COPD), heart disease, renal disease, diabetes, and 
cancer are known to be at substantially increased risk for serious complications from 
influenza (1-3). Vaccination of persons with high-risk conditions is a key public health 
strategy in preventing influenza-related morbidity and mortality in the United States (2). 
Optimal use of vaccination strategies can not only reduce influenza-related morbidity and 
mortality but can also minimize missed work days due to illness (2). Persons with high-risk 
conditions were recommended for annual influenza vaccination by the Public Health Service 
as early as 1960 (4). Prior to 2010, the Advisory Committee on Immunization Practices 
(ACIP) recommended yearly vaccination for adults ≥ 50 years and adults 18-49 years with 
high-risk conditions (5). Since the 2010-11 season, the ACIP has recommended annual 
influenza vaccination for all adults (1, 2, 5).
Before Healthy People 2020 influenza vaccination objectives were consolidated following 
the ACIP recommendation for universal vaccination of adults, the annual influenza 
vaccination target for adults 18-64 years with high-risk conditions was 90%. The current 
revised vaccination target for all adults ≥18 years is 70% (6); however, ACIP continues to 
emphasize that persons with high-risk conditions should be a focus of vaccination efforts 
(5). Despite the long-standing ACIP recommendations, vaccination levels among persons 
with medical conditions that increase risk for complications from influenza have remained 
suboptimal (7-11). To evaluate the impact of the current adult influenza vaccination program 
in the United States for persons with high-risk conditions, we assessed national influenza 
vaccination coverage and potential missed opportunities for vaccination among adults 18-64 
years with underlying high-risk conditions using data from the National Health Interview 
Survey (NHIS). We also evaluated demographic and access-to-care factors associated with 
receipt of influenza vaccination to identify potential strategies to improve vaccination 
coverage.
Methods
We analyzed data from the 2012 and 2013 NHIS. NHIS is a probability based annual 
household survey conducted by the National Center for Health Statistics of the Centers for 
Disease Control and Prevention (12-13). The survey has four main modules: the household 
composition section, family core, sample adult core, and sample child core. In the sample 
adult core, one adult per sampled family was randomly selected and asked to complete the 
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sample adult questionnaire, including questions about receipt of influenza vaccination. In 
2012 and 2013, the final response rates for the sample adult core were 61.2% for both years 
(12-13).
We defined high-risk persons as individuals who self-reported one or more of the following: 
ever being told by a physician they had diabetes, emphysema, COPD, coronary heart 
disease, angina, heart attack or other heart condition; being diagnosed with cancer in the past 
12 months (excluding non-melanoma skin cancer) or ever being told by a physician they 
have lymphoma, leukemia or blood cancer; during the past 12 months, being told by a 
physician they have chronic bronchitis or weak or failing kidneys; or reporting an asthma 
episode or attack in the past 12 months. Poverty status was defined as a total family income 
of <$23,492, and <23,624 for a family of four for 2012 and 2013, respectively, using poverty 
thresholds published by the U.S. Census Bureau (14).
SUDAAN (Software for the statistical analysis of correlated data, Research Triangle 
Institute, Research Triangle Park, NC, version 10.01) was used to calculate point estimates 
and 95% confidence intervals (CIs). In bivariate analyses, we assessed influenza vaccination 
among adults 18-64 years with high-risk conditions stratified by demographic and access-to-
care variables. Chi-square and t-tests were used to determine differences between groups 
with statistical significance at p < 0.05. To better assess seasonal influenza vaccination 
coverage, we reported coverage restricted to individuals interviewed during August 2012 
through June 2013, and vaccinated during July 2012 through May 2013 using the Kaplan-
Meier survival analysis procedure. Multivariable logistic regression and predictive marginal 
models were used to generate adjusted prevalence ratios and identify variables 
independently associated with reported receipt of influenza vaccination in the past 12 
months (15, 16). All variables used in the bivariate analysis were included in the full 
multivariable model. To assess potential missed opportunities for influenza vaccination 
among adults with high-risk conditions, we calculated the proportions of persons who 
reported not receiving influenza vaccination in the 2012-13 influenza season by selected 
health care access characteristics.
Results
Table 1 shows the baseline demographic characteristics of the study population.
The overall influenza vaccination coverage for the 2012-13 season among adults 18-64 years 
with high-risk conditions was 49.5%. Vaccination coverage for the 2012-13 season among 
adults with high-risk conditions was significantly lower among adults 18-49 years at 39.0% 
compared with 59.3% for adults 50-64 years (Table 2). Vaccination coverage for adults 
18-64 years with high-risk conditions was 49.0% for non-Hispanic whites, 45.8% for non-
Hispanic blacks, 49.4% for Hispanics, 65.9% for Asians, and 60.6% for those reporting 
other race (Table 2). Coverage was significantly higher among Asians compared with non-
Hispanic whites (p<0.05) (Table 2). Coverage for adults 18-64 years with high-risk 
conditions was significantly higher among adults with at least some college education, who 
were employed, and living at or above poverty level (Table 2) (p<0.05). Additionally, 
coverage was significantly lower among adults who were never married, and those who were 
Lu et al. Page 3
Am J Med. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
born outside the United States and were in the United States less than 10 years (Table 2) 
(p<0.05).
Among adults 18-64 years with high-risk conditions, vaccination coverage was higher for 
those who had any physician contacts during the past year compared with those with none, 
and increased with higher numbers of physician contacts. There was almost a 40 percentage-
point difference in proportion vaccinated between those who had no physician contacts and 
those who had 10 or more physician contacts in the past year (Table 2). Persons who had 
been hospitalized in the past year were significantly more likely to have received influenza 
vaccination than those who were not. There was a 38 percentage-point difference in 
vaccination coverage between those who had a regular physician for health care and those 
who did not have one. Coverage was significantly higher (p<0.05) among adults with health 
insurance (55.1%) compared with those without health insurance (23.9%) and among adults 
who had ever received pneumococcal vaccination (73.4%) compared with those who had not 
(38.7%) (p<0.05 for both comparisons) (Table 2). Vaccination coverage was significantly 
higher among adults 50-64 years compared with adults 18-49 years across most socio-
demographic and access-to-care characteristics (Table 2).
In multivariable analysis, among adults 18-64 years with high-risk conditions, older age, 
being female, Hispanic ethnicity or Asian race, having one or more physician visits, a 
regular physician for health care, health insurance, and having ever received pneumococcal 
vaccination were independently associated with a higher likelihood of influenza vaccination. 
Being widowed/divorced/separated and not being employed were independently associated 
with a lower likelihood of influenza vaccination (Table 3). Among adults 18-49 years with 
high-risk conditions, characteristics independently associated with a higher likelihood of 
vaccination were similar to those for 18-64 years. Never having been married and not being 
employed were independently associated with a lower likelihood of vaccination (Table 3). 
Among adults 50-64 years with high-risk conditions, Hispanic ethnicity, having two or more 
physician visits, a regular physician for health care, health insurance, and having ever 
received pneumococcal vaccination were independently associated with a higher likelihood 
of vaccination (Table 3).
Among adults 18-64 years, influenza vaccination coverage in the 2012-13 season was 49.5% 
among those with at least one high-risk condition, 59.5% among those with at least two 
high-risk conditions, 46.2% among those with lung disease, 50.5% among those with heart 
disease, 58.0% among those with diabetes, 62.5% among those with renal disease, and 
56.4% among those with cancer (Table 4). Additionally, most condition-specific vaccination 
coverage was significantly higher among persons 50-64 years compared with persons 18-49 
years (Table 4).
Potential missed opportunities for influenza vaccination were also evaluated. Among adults 
18-64 years with at least one high-risk condition who reported not receiving influenza 
vaccination in the 2012-13 season, 87.3% had one or more physician contacts in the last 12 
months, 15.2% were hospitalized in past year, and 31.7% had visited an emergency room 
(ER). Overall, 90.1% reported at least one visit to a health care setting where vaccination 
could have been provided. Among persons reporting ≥ 2 ER visits, the proportion was 
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significantly higher among non-Hispanic blacks (25.2%). Among those with at least one 
potential missed opportunity, Hispanics had the lowest proportion (85.2%) (Table 5).
Discussion
Findings from this study demonstrate that among adults 18-64 years with high-risk 
conditions, influenza vaccination coverage was low overall as well as among those with 
multiple high-risk conditions. During the 2012-13 season, about 40-60% of adults 18-64 
years at increased risk for influenza were unvaccinated against influenza. Vaccination 
coverage remained well below the previous Healthy People 2020 target of 90% for all the 
influenza high-risk groups studied and below the current target of 70% set for all adults (6).
Factors associated with lower influenza vaccination coverage among adults with high-risk 
conditions have been described in other studies and might include: lack of a preexisting 
relationship of state immunization programs with providers who serve adults at high risk; 
difficulty in implementing a risk-condition-based vaccination recommendation; persons with 
underlying health conditions not considering themselves as high risk limiting the 
effectiveness of targeted messages; and, historically low seasonal influenza vaccination 
coverage in this population (5, 7-11, 17).
Several ongoing programs or disease-related professional organizations have supported 
intensive efforts to improve influenza vaccination among persons with high-risk conditions 
(18-21). For example, the Diabetes Quality Improvement Project, a collaborative effort 
between public and private organizations to improve preventive care for persons with 
diabetes, including influenza vaccination, has been ongoing for more than 10 years (18, 19). 
The National Asthma Education and Prevention Program panel identified influenza 
vaccination as one of several “key clinical activities that should be considered as essential 
for quality asthma care” (20). The American Heart Association/American College of 
Cardiology together with other heart disease organizations recommended influenza 
vaccination as secondary prevention for cardiovascular disease (21). In addition, the 
Department of Health and Human Services (HHS) initiated a strategic framework to improve 
the health status of individuals with multiple chronic conditions (22-24). The HHS 
framework contains a vision statement, goals, objectives, and discrete strategies for 
individuals with multiple chronic conditions to guide the department in coordinating its 
efforts internally and externally through collaborating with stakeholders to improve care 
coordination, maximize the use of proven self-care management and other services, provide 
better tools and information to providers who deliver care to persons with multiple chronic 
conditions, and facilitate research to fill knowledge gaps and develop beneficial 
interventions. The framework outlines national strategies for improving health and quality of 
life for individuals with multiple chronic conditions, including maximizing use of proven 
services like vaccination (22-24). Those ongoing activities may help improve influenza 
vaccination coverage among persons with high-risk conditions.
As might be expected, this study found that vaccination coverage among persons 50-64 
years was significantly higher than among those 18-49 years. This result remained after 
controlling for other demographic and access to care variables. As people age, the 
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prevalence of high-risk conditions is likely to increase. In this study, the prevalence of lung 
disease, heart disease, and diabetes among adults 50-64 years were 10.8%, 13.8%, and 
13.8%, respectively, compared with 6.3%, 4.6%, and 3.4%, respectively, among adults 18-49 
years. Healthcare providers may be more likely to recommend influenza vaccination to 
persons 50-64 years with high-risk conditions because of a perception of greater risk for 
complications from influenza compared with younger persons 18-49 years (25). Healthcare 
providers should ensure that persons at high risk receive appropriate vaccinations regardless 
of age.
Influenza vaccination coverage also varied substantially among persons with specific high-
risk conditions, ranging from 44.0% for adults with asthma to 62.5% for those with renal 
disease. Lower coverage for adults with asthma might reflect their concerns that the vaccine 
could trigger an asthma exacerbation making them less likely to be vaccinated, although 
studies found no evidence of asthma exacerbation or other severe side effects after influenza 
vaccination (26-28). Given that respiratory infections such as influenza can be serious in 
persons with asthma, the lower vaccination coverage in this risk group warrants further 
consideration (29). Offering influenza vaccination in the ER to those with asthma would be 
appropriate. Sometimes ERs may be the only place these patients interact with a medical 
provider (20). Physicians should consider each office or ER visit a potential opportunity to 
vaccinate persons with asthma (20).
We found that vaccination coverage among persons who have health insurance, have a 
regular physician for health care, and physician contacts in past 12 months were 
significantly associated with influenza vaccination. These findings remained after 
controlling for other variables and are consistent with other reports (8, 9, 30). Physician 
contact plays an important role in vaccination uptake (8, 9, 31). Having a regular physician 
and seeing a physician provide opportunities for education about influenza vaccination and 
offering vaccination and other prevention services. Persons with high-risk conditions may 
have more frequent contacts with their healthcare providers. Routine physician visits can 
provide important opportunities for providers to vaccinate persons with high-risk conditions.
There were missed opportunities for vaccinating adults with high-risk conditions. Although 
our findings suggest that recent physician contacts were independently associated with 
influenza vaccination, we also found a substantial proportion of individuals with high-risk 
conditions who had visited their physicians at least 10 times within the past year, but still 
were not vaccinated. Based on our study, overall, 90.1% of unvaccinated individuals 
reported at least one visit to a health care setting where vaccination could have been 
provided including 87.3% who had one or more physician contacts in the last 12 months, 
15.2% who were hospitalized in the previous 12 months, and 31.7% who had visited an 
emergency room. In one study, a significant proportion of generalists and subspecialists 
failed to recommend influenza vaccination to their high-risk patients (17). Use of standing 
order programs might help reduce the number of missed opportunities for vaccinating 
persons who have already accessed the medical system (32-34). In addition, it is also 
important for subspecialists to recommend and offer influenza vaccination to high-risk 
adults. Although primary care physicians are the predominant providers for adults with 
chronic conditions in the health care system, subspecialists also see these patients with great 
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frequency (35). However, one study indicated that about 22% of subspecialists did not stock 
the influenza vaccine. The most common factor in the decision to not stock vaccine was the 
perception that patients will receive the vaccine elsewhere (35). Subspecialists were less 
likely to stock and recommend influenza vaccine, especially cardiologists (35, 36). To 
reduce missed opportunities overall, subspecialists should be encouraged to vaccinate high-
risk patients or refer their patients for vaccination (35, 35).
One limitation should be considered in interpreting these results. Information on influenza 
vaccination was self-reported and may be subject to recall bias. However, self-reported 
seasonal influenza vaccination status among older adults has been shown to have relatively 
high agreement with vaccination status ascertained from medical records (37-39).
Influenza vaccination coverage among adults with high-risk conditions remains suboptimal. 
In 2012-13, an estimated 40 million adults 18-64 years had underlying medical conditions, 
but only about 50% had received the vaccine and 90% of unvaccinated individuals may have 
missed at least one potential opportunity for receiving vaccination. Even though the 
influenza vaccination was expanded to include all persons ≥ 6 months of age in the 2010-11 
season, the ACIP continued to emphasize that persons with high-risk conditions should be a 
focus of vaccination efforts (5). Substantial improvement in annual influenza vaccination of 
adults with high-risk conditions is needed to maximally reduce the health impact of 
influenza. Primary care providers, subspecialists, and pharmacists should routinely 
recommend and offer vaccinations when patients access the medical system (40). Expanded 
access through greater use of complimentary settings and vaccine providers, and better use 
of evidence-based practices at medical sites (e.g., standing orders, and reminder/recall 
notification) are important to improving influenza vaccination coverage further (33, 41).
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TABLE 3
Multivariable logistic regression and predictive marginal analysis* of influenza vaccination among adults 
18-64 years with high-risk conditions† in the United States, by demographic and access-to-care 
characteristics--NHIS 2012-13
Characteristics
Age group
18-64 years 18-49 years 50-64 years
PR (95% CI) PR (95% CI) PR (95% CI)
Age
18-49 years Reference NA NA
50-64 years 1.27 (1.17, 1.39)‡ NA NA
Sex
Male Reference Reference Reference
Female 1.12 (1.03, 1.21)‡ 1.24 (1.07, 1.44)‡ 1.05 (0.96, 1.15)
Race/ethnicity
Non-Hispanic White Reference Reference Reference
Non-Hispanic Black 0.94 (0.83, 1.06) 1.00 (0.82, 1.22) 0.90 (0.78, 1.05)
Hispanic 1.21 (1.07, 1.37)‡ 1.26 (1.03, 1.54)‡ 1.19 (1.03, 1.38)‡
Asian 1.33 (1.10, 1.63)‡ 1.64 (1.25, 2.17)‡ 1.16 (0.90, 1.51)
Other 1.21 (0.98, 1.50) 1.39 (1.03, 1.87) 1.10 (0.83, 1.45)
Marital status
Married Reference Reference Reference
Widowed/divorced/separated 0.89 (0.81, 0.97)‡ 0.85 (0.70, 1.03) 0.92 (0.84, 1.01)
Never married 0.93 (0.85, 1.02) 0.86 (0.74, 1.00)‡ 1.01 (0.89, 1.14)
Education
< High school Reference Reference Reference
High school graduate 0.95 (0.83, 1.10) 0.92 (0.71, 1.19) 0.98 (0.84, 1.15)
Some college+ 1.10 (0.98, 1.25) 1.05 (0.86, 1.29) 1.13 (0.98, 1.30)
Employment status
Employed Reference Reference Reference
Not employed 0.81 (0.68, 0.97)‡ 0.77 (0.58, 1.02)‡ 0.84 (0.65, 1.07)
Not in work force 0.95 (0.87, 1.04) 0.93 (0.78, 1.12) 0.96 (0.87, 1.06)
Poverty level
At or above poverty 1.08 (0.97, 1.21) 1.12 (0.91, 1.37) 1.05 (0.93, 1.20)
Below poverty Reference Reference Reference
US born status
U.S. born Reference Reference Reference
Born outside U.S. -- In U.S. ≤ 10 yrs 1.02 (0.79, 1.33) 0.96 (0.66, 1.40) 1.01 (0.60, 1.72)
Born outside U.S. -- In U.S. > 10 yrs 1.03 (0.90, 1.17) 0.99 (0.78, 1.25) 1.05 (0.88, 1.24)
Region of residence
Northeast Reference Reference Reference
Midwest 1.01 (0.90, 1.15) 1.02 (0.83, 1.26) 1.02 (0.88, 1.18)
Am J Med. Author manuscript; available in PMC 2018 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lu et al. Page 17
Characteristics
Age group
18-64 years 18-49 years 50-64 years
PR (95% CI) PR (95% CI) PR (95% CI)
South 0.98 (0.88, 1.10) 0.98 (0.83, 1.17) 1.00 (0.87, 1.14)
West 0.99 (0.88, 1.11) 1.02 (0.84, 1.25) 0.97 (0.83, 1.14)
Physician contacts within past year
None Reference Reference Reference
1 1.27 (1.00, 1.63)‡ 1.32 (0.92, 1.90) 1.25 (0.92, 1.71)
2-3 1.47 (1.18, 1.83)‡ 1.53 (1.10, 2.13)‡ 1.41 (1.05, 1.90)‡
4-9 1.48 (1.18, 1.85)‡ 1.53 (1.11, 2.10)‡ 1.43 (1.05, 1.95)‡
>10 1.54 (1.22, 1.93)‡ 1.53 (1.07, 2.18)‡ 1.52 (1.12, 2.06)‡
Hospitalization within past year
Yes 1.05 (0.94, 1.17) 1.11 (0.91, 1.37) 1.01 (0.90, 1.13)
No Reference Reference Reference
Regular physician
Yes 1.68 (1.33, 2.11)‡ 1.58 (1.17, 2.12)‡ 2.22 (1.44, 3.43)‡
No Reference Reference Reference
Health insurance
With health insurance 1.41 (1.21, 1.64)‡ 1.52 (1.21, 1.92)‡ 1.34 (1.10, 1.64)‡
Without health insurance Reference Reference Reference
Ever received pneumococcal vaccination
Yes 1.76 (1.63, 1.89)‡ 2.06 (1.80, 2.36)‡ 1.58 (1.44, 1.72)‡
No Reference Reference Reference
*
Participants interviewed August 2012-June 2013 and vaccinated within the past 12 months from date of interview.
†
High-risk definition: adults categorized as at high risk for influenza-related complications self-reported 1 or more of the following: (1) ever being 
told by a physician they had diabetes, emphysema, chronic obstructive pulmonary disease, coronary heart disease, angina, heart attack, or other 
heart condition; (2) having a diagnosis of cancer during the preceding 12 months (excluding nonmelanoma skin cancer) or ever being told by a 
physician they have lymphoma, leukemia, or blood cancer; (3) being told by a physician they have chronic bronchitis or weak or failing kidneys; or 
(4) reporting an asthma episode or attack during the preceding 12 months.
‡p < 0.05 compared with the reference level.
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r b
lo
od
 c
an
ce
r; 
(3)
 be
ing
 to
ld 
by
 a 
ph
ys
ic
ia
n 
th
ey
 h
av
e 
ch
ro
ni
c 
br
on
ch
iti
s o
r w
ea
k 
or
 fa
ili
ng
 k
id
ne
ys
; o
r (
4) 
rep
ort
ing
 an
 as
thm
a e
pis
od
e o
r 
at
ta
ck
 d
ur
in
g 
th
e 
pr
ec
ed
in
g 
12
 m
on
th
s.
† In
cl
ud
es
 A
ug
us
t 2
01
2-
Ju
ne
 2
01
3 
in
te
rv
ie
w
s;
 e
st
im
at
es
 th
e 
pr
op
or
tio
n 
of
 a
du
lts
 w
ith
 h
ig
h-
ris
k 
co
nd
iti
on
s w
ho
 h
ad
 n
ot
 re
ce
iv
ed
 in
flu
en
za
 v
ac
ci
na
tio
n 
fro
m
 Ju
ly
 2
01
2 
th
ro
ug
h 
M
ay
 2
01
3.
‡ In
di
ca
te
s p
<0
.0
5 
(ch
i-s
qu
are
 te
st 
for
 as
so
cia
tio
n b
etw
ee
n r
ac
e/e
thn
ici
ty,
 
N
H
-w
hi
te
 is
 th
e 
re
fe
re
nc
e 
gr
ou
p).
§ In
di
ca
te
s p
er
so
ns
 re
po
rte
d 
on
e 
m
or
e 
of
 th
e 
fo
llo
w
in
g:
 h
ad
 a
t l
ea
st 
on
e 
do
ct
or
 v
isi
t, 
ho
sp
ita
liz
ed
 in
 th
e 
pa
st 
ye
ar
,
 
ha
d 
at
 le
as
t o
ne
 E
R 
vi
sit
.
Am J Med. Author manuscript; available in PMC 2018 March 01.
